Hanmi Science (008930) - Net Assets
Based on the latest financial reports, Hanmi Science (008930) has net assets worth ₩959.19 Billion KRW (≈ $650.03 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩1.49 Trillion ≈ $1.01 Billion USD) and total liabilities (₩529.85 Billion ≈ $359.07 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Hanmi Science to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩959.19 Billion |
| % of Total Assets | 64.42% |
| Annual Growth Rate | 9.88% |
| 5-Year Change | 38.95% |
| 10-Year Change | 48.12% |
| Growth Volatility | 16.11 |
Hanmi Science - Net Assets Trend (2000–2025)
This chart illustrates how Hanmi Science's net assets have evolved over time, based on quarterly financial data. Also explore Hanmi Science balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Hanmi Science (2000–2025)
The table below shows the annual net assets of Hanmi Science from 2000 to 2025. For live valuation and market cap data, see how much is Hanmi Science worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩959.19 Billion ≈ $650.03 Million |
+14.37% |
| 2024-12-31 | ₩838.70 Billion ≈ $568.38 Million |
+6.51% |
| 2023-12-31 | ₩787.47 Billion ≈ $533.66 Million |
+8.65% |
| 2022-12-31 | ₩724.75 Billion ≈ $491.15 Million |
+4.99% |
| 2021-12-31 | ₩690.29 Billion ≈ $467.80 Million |
+4.79% |
| 2020-12-31 | ₩658.73 Billion ≈ $446.41 Million |
+2.02% |
| 2019-12-31 | ₩645.69 Billion ≈ $437.57 Million |
-1.13% |
| 2018-12-31 | ₩653.09 Billion ≈ $442.59 Million |
-1.81% |
| 2017-12-31 | ₩665.15 Billion ≈ $450.76 Million |
+2.72% |
| 2016-12-31 | ₩647.56 Billion ≈ $438.84 Million |
+10.84% |
| 2015-12-31 | ₩584.25 Billion ≈ $395.94 Million |
+39.87% |
| 2014-12-31 | ₩417.71 Billion ≈ $283.08 Million |
+2.11% |
| 2013-12-31 | ₩409.07 Billion ≈ $277.22 Million |
+3.85% |
| 2012-12-31 | ₩393.89 Billion ≈ $266.94 Million |
+5.81% |
| 2011-12-31 | ₩372.25 Billion ≈ $252.27 Million |
-38.45% |
| 2010-12-31 | ₩604.83 Billion ≈ $409.88 Million |
+35.95% |
| 2009-12-31 | ₩444.88 Billion ≈ $301.49 Million |
+13.20% |
| 2008-12-31 | ₩393.00 Billion ≈ $266.33 Million |
+12.02% |
| 2007-12-31 | ₩350.82 Billion ≈ $237.74 Million |
+20.49% |
| 2006-12-31 | ₩291.16 Billion ≈ $197.32 Million |
+32.55% |
| 2005-12-31 | ₩219.66 Billion ≈ $148.86 Million |
+20.82% |
| 2004-12-31 | ₩181.81 Billion ≈ $123.21 Million |
+16.83% |
| 2003-12-31 | ₩155.62 Billion ≈ $105.46 Million |
+6.27% |
| 2002-12-31 | ₩146.43 Billion ≈ $99.23 Million |
+11.19% |
| 2001-12-31 | ₩131.69 Billion ≈ $89.25 Million |
+44.82% |
| 2000-12-31 | ₩90.93 Billion ≈ $61.62 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Hanmi Science's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 98751.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩757.96 Billion | 78.80% |
| Other Components | ₩203.89 Billion | 21.20% |
| Total Equity | ₩961.85 Billion | 100.00% |
Hanmi Science Competitors by Market Cap
The table below lists competitors of Hanmi Science ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Beijing Bei Mo Gao Ke Friction Mate
SHE:002985
|
$1.73 Billion |
|
Anhui Xinhua Media Co Ltd
SHG:601801
|
$1.73 Billion |
|
Amara Raja Batteries Limited
NSE:ARE&M
|
$1.73 Billion |
|
Sinomag Technology Co Ltd
SHE:300835
|
$1.73 Billion |
|
Shanghai Geoharbour Construction Group Co Ltd
SHG:605598
|
$1.73 Billion |
|
Deepak Fertilizers and Petrochemicals Corporation Limited
NSE:DEEPAKFERT
|
$1.73 Billion |
|
NP3 Fastigheter AB
ST:NP3
|
$1.73 Billion |
|
Cimpress NV
NASDAQ:CMPR
|
$1.73 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hanmi Science's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 840,928,986,270 to 961,852,859,660, a change of 120,923,873,390 (14.4%).
- Net income of 118,369,957,150 contributed positively to equity growth.
- Dividend payments of 13,542,741,200 reduced retained earnings.
- Other factors increased equity by 16,096,657,440.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩118.37 Billion | +12.31% |
| Dividends Paid | ₩13.54 Billion | -1.41% |
| Other Changes | ₩16.10 Billion | +1.67% |
| Total Change | ₩- | 14.38% |
Book Value vs Market Value Analysis
This analysis compares Hanmi Science's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.65x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.67x to 2.65x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩10280.35 | ₩37700.00 | x |
| 2018-12-31 | ₩10095.47 | ₩37700.00 | x |
| 2019-12-31 | ₩9982.34 | ₩37700.00 | x |
| 2020-12-31 | ₩10185.62 | ₩37700.00 | x |
| 2021-12-31 | ₩10261.19 | ₩37700.00 | x |
| 2022-12-31 | ₩10871.82 | ₩37700.00 | x |
| 2023-12-31 | ₩11583.95 | ₩37700.00 | x |
| 2024-12-31 | ₩12418.89 | ₩37700.00 | x |
| 2025-12-31 | ₩14204.70 | ₩37700.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hanmi Science utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 12.31%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.72%
- • Asset Turnover: 0.91x
- • Equity Multiplier: 1.55x
- Recent ROE (12.31%) is above the historical average (11.03%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | 12.09% | 7.10% | 0.61x | 2.81x | ₩1.84 Billion |
| 2001 | 17.44% | 10.75% | 0.66x | 2.45x | ₩9.00 Billion |
| 2002 | 15.98% | 8.46% | 0.83x | 2.29x | ₩7.99 Billion |
| 2003 | 8.40% | 4.43% | 0.81x | 2.34x | ₩-2.24 Billion |
| 2004 | 18.23% | 8.70% | 0.94x | 2.22x | ₩13.54 Billion |
| 2005 | 20.22% | 10.57% | 0.97x | 1.98x | ₩21.15 Billion |
| 2006 | 26.43% | 16.33% | 0.85x | 1.91x | ₩45.13 Billion |
| 2007 | 16.01% | 9.97% | 0.77x | 2.08x | ₩19.89 Billion |
| 2008 | 19.53% | 11.79% | 0.72x | 2.29x | ₩34.92 Billion |
| 2009 | 12.10% | 7.32% | 0.77x | 2.14x | ₩8.77 Billion |
| 2010 | 1.54% | 0.92% | 0.63x | 2.66x | ₩-32.71 Billion |
| 2012 | 3.18% | 61.85% | 0.04x | 1.24x | ₩-26.79 Billion |
| 2013 | 2.35% | 4.35% | 0.38x | 1.42x | ₩-31.21 Billion |
| 2014 | 5.12% | 4.00% | 0.72x | 1.79x | ₩-20.29 Billion |
| 2015 | 30.59% | 22.99% | 0.83x | 1.60x | ₩120.15 Billion |
| 2016 | 1.23% | 1.19% | 0.69x | 1.50x | ₩-56.59 Billion |
| 2017 | 4.52% | 4.61% | 0.69x | 1.41x | ₩-36.45 Billion |
| 2018 | 2.76% | 2.55% | 0.77x | 1.40x | ₩-47.29 Billion |
| 2019 | 4.76% | 3.76% | 0.90x | 1.41x | ₩-33.83 Billion |
| 2020 | 3.43% | 2.64% | 0.93x | 1.40x | ₩-43.27 Billion |
| 2021 | 6.22% | 4.52% | 1.00x | 1.38x | ₩-26.09 Billion |
| 2022 | 9.55% | 6.62% | 0.94x | 1.53x | ₩-3.27 Billion |
| 2023 | 14.62% | 9.23% | 1.02x | 1.56x | ₩36.37 Billion |
| 2024 | 7.07% | 4.63% | 0.95x | 1.60x | ₩-24.67 Billion |
| 2025 | 12.31% | 8.72% | 0.91x | 1.55x | ₩22.18 Billion |
Industry Comparison
This section compares Hanmi Science's net assets metrics with peer companies in the Medical Distribution industry.
No peer company data available for comparison.
About Hanmi Science
Hanmi Science Co., Ltd., through its subsidiaries, manufactures and sells pharmaceutical products in Korea and internationally. It develops drugs in the areas of diabetes and anti-cancer, as well as children's and adult's bowel preparation and cold medicines, and cephalosporin antibiotics. The company also offers general foods, health functional foods, soy milk, and medical equipment. In addition… Read more